Novo Nordisk报告销售增长强劲,但由于竞争,2025年的预测低于2025年的预测。 Novo Nordisk reports strong sales growth but lowers 2025 forecast due to competition.

丹麦制药巨头Novo Nordisk报告,2025年上半年销售额增长16%,达到1549亿丹麦克朗,营业利润增长25%。 Danish pharma giant Novo Nordisk reported a 16% sales increase to DKK 154.9 billion in the first half of 2025, with operating profit up 25%. 尽管美国和国际业务以及糖尿病和肥胖症护理增长强劲——其减重药物Wegovy的销售额增长了67%——诺沃公司由于竞争加剧和市场扩张放缓,将2025年的预测增长率降至8-14%。 Despite strong growth in US and international operations and in diabetes and obesity care—where its weight-loss drug Wegovy saw a 67% sales increase—Novo lowered its 2025 growth forecast to 8-14% due to increased competition and slower market expansion. 该公司还对药店和生产其药物通用版本的远程保健公司提起诉讼。 The company also filed lawsuits against pharmacies and telehealth companies producing generic versions of its drugs.